TRAIL Mediated Signaling in Pancreatic Cancer |
Nogueira, Daniele Rubert
(Department of Industrial Pharmacy, Health Science Center, Federal University of Santa Maria)
Yaylim, Ilhan (Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul University) Aamir, Qurratulain (Department of Anatomy, Rashid Latif Medical College) Kahraman, OzlemTimirci (Department of Molecular Medicine, Institute of Experimental Medicine, Istanbul University) Fayyaz, Sundas (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) Naqvi, Syed Kamran-Ul-Hassan (COMSATS Institute of Information Technology) Farooqi, Ammad Ahmad (Laboratory for Translational Oncology and Personalized Medicine, Rashid Latif Medical College) |
1 | Kong R, Jia G, Cheng ZX, et al (2012). Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One, 7, 37222. DOI |
2 | LaCasse EC, Cherton-Horvat GG, Hewitt KE, et al (2006). Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res, 12, 5231-41. DOI ScienceOn |
3 | Lan X, Sun H, Liu J, et al (2013). Effects of garlic oil on pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 5905-10. 과학기술학회마을 DOI ScienceOn |
4 | Lee AL, Dhillon SH, Wang Y, et al (2011). Synergistic anticancer effects via co-delivery of TNF-related apoptosisinducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. MolBiosyst, 7, 1512-22. |
5 | Lee AL, Wang Y, Pervaiz S, Fan W, Yang YY (2011). Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles. MacromolBiosci, 11, 296-307. |
6 | Liao Q, Friess H, Kleeff J, Buchler MW (2001). Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res, 21, 3153-9. |
7 | Lim SM, Kim TH, Jiang HH, et al (2011). Improved biological half-life and anti-tumor activity of TNF-related apoptosisinducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials, 32, 3538-46. DOI ScienceOn |
8 | Liu Q, Chen W, Jiao Y, et al (2014). Pulsatilla saponin A, an active molecule from Pulsatilla chinensis, induces cancer cell death and inhibits tumor growth in mouse xenograft models. J Surg Res, 188, 387-95. DOI ScienceOn |
9 | Liu Y, Cui YF (2013). Synergism of cytotoxicity effects of triptolide and artesunate combination treatment in pancreatic cancer cell lines. Asian Pac J Cancer Prev, 14, 5243-8. 과학기술학회마을 DOI ScienceOn |
10 | Mangipudi SS, Canine BF, Wang Y, Hatefi A (2009). Development of a genetically engineered biomimetic vector for targeted gene transfer to breast cancer cells. Mol Pharm, 6, 1100-9. DOI ScienceOn |
11 | Matsuzaki H, Schmied BM, Ulrich A, et al (2001). Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. Clin Cancer Res, 7, 407-14. |
12 | Miao L, Zhang K, Qiao C, et al (2013). Antitumor effect of human TRAIL on adenoid cystic carcinoma using magnetic nanoparticle-mediated gene expression. Nanomedicine, 9, 141-50. DOI ScienceOn |
13 | Ozawa F, Friess H, Kleeff J, et al (2001). Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett, 163, 71-81. DOI ScienceOn |
14 | Petrangolini G, Tortoreto M, Perego P, et al (2008). Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer BiolTher, 7, 596-601. |
15 | Roder C, Trauzold A, Kalthoff H (2011). Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol, 90, 450-5. DOI ScienceOn |
16 | Sharma R, Buitrago S, Pitoniak R, et al (2014). Influence of the implantation site on the sensitivity of patient pancreatic tumor xenografts to Apo2L/TRAIL therapy. Pancreas, 43, 298-305. DOI ScienceOn |
17 | Trauzold A, Wermann H, Arlt A, et al (2001). CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene, 20, 4258-69. DOI ScienceOn |
18 | Stadel D, Mohr A, Ref C, et al (2010). TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res, 16, 5734-49. DOI ScienceOn |
19 | Stan SD, Singh SV, Whitcomb DC, Brand RE (2013). Phenethyl isothiocyanate inhibits proliferation and induces apoptosis in pancreatic cancer cells in vitro and in a MIAPaca2 xenograft animal model. Nutr Cancer, 66, 747-55. |
20 | Thomas RP, Farrow BJ, Kim S, et al (2002). Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery, 132, 127-34. DOI ScienceOn |
21 | Vogler M, Walczak H, Stadel D, et al (2008). Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. Cancer Res, 68, 7956-65. DOI ScienceOn |
22 | Wang Y, Zhou Y, Jia G, et al (2014). Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: involvement of NF-kB signaling pathway. Biochem Pharmacol, 88, 322-33. DOI ScienceOn |
23 | Zhang JS, Herreros-Vilanueva M, Koenig A, et al (2014). Differential activity of GSK-3 isoforms regulates NF-kB andTRAIL- or induced apoptosis in pancreatic cancer cells. Cell Death Dis, 5, 1142. DOI ScienceOn |
24 | Zhao B, Li L, Cui K, et al (2011). Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis. Asian Pac J Cancer Prev, 12, 2675-8. |
25 | Braeuer SJ, Buneker C, Mohr A, Zwacka RM (2006). Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by upregulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol Cancer Res, 4, 715-28. DOI ScienceOn |
26 | Zhou DH, Yang LN, Roder C, Kalthoff H, Trauzold A (2013). TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xl in pancreatic ductal adenocarcinoma cells. Hepatobiliary Pancreat Dis Int, 12, 94-8. DOI ScienceOn |
27 | Arlt A, Muerkoster SS, Schafer H (2013). Targeting apoptosis pathways in pancreatic cancer. Cancer Lett, 332, 346-58. DOI ScienceOn |
28 | Bae S, Ma K, Kim TH, et al (2012). Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials, 33, 1536-46. DOI ScienceOn |
29 | Bai J, Sui J, Demirjian A, et al (2005). Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res, 65, 2344-52. DOI ScienceOn |
30 | Basu A, Haldar S (2009). Anti-proliferative and proapoptotic effects of benzyl isothiocyanate on human pancreatic cancer cells is linked to death receptor activation and RasGAP/Rac1 down-modulation. Int J Oncol, 35, 593-9. |
31 | Byeon HJ, Choi SH, Choi JS, et al (2013). Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosisinducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Biomed Pharmacother, 68, 65-9. |
32 | Byeon HJ, Choi SH, Choi JS, et al (2014). Four-arm PEG crosslinked hyaluronic acid hydrogels containing PEGylated apoptotic TRAIL protein for treating pancreatic cancer. ActaBiomater, 10, 142-50. |
33 | Chen S, Wang G, Niu X, et al (2014). Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. Feb, 348, 20-8. DOI ScienceOn |
34 | Chen Z, Sangwan V, Banerjee S, et al (2014). Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett, 348, 156-66. DOI ScienceOn |
35 | Diamantidis M, Tsapournas G, Kountouras J, Zavos C (2008). New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med, 8, 12-37. DOI ScienceOn |
36 | Ding J, Polier G, Kohler R, et al (2012). Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and upregulation of TRAIL receptor 2 expression. J Biol Chem, 287, 641-9. DOI |
37 | Ding N, Cui XX, Gao Z, et al (2014). A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors. Int J Oncol, 44, 2139-45. |
38 | Garg G, Gibbs J, Belt B, et al (2014). Novel treatment option for MUC16-positive malignancies with the targeted TRAILbased fusion protein Meso-TR3. BMC Cancer, 14, 35. DOI ScienceOn |
39 | Forero-Torres A, Infante JR, Waterhouse D, et al (2013). Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer. Cancer Med, 2, 925-32. DOI |
40 | Fu J, Rodova M, Roy SK, et al (2013). GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett, 330, 22-32. DOI ScienceOn |
41 | Groth A, Salnikov AV, Ottinger S, et al (2012). New geneimmunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin Cancer Res, 18, 1028-38. DOI ScienceOn |
42 | Guo L, Fan L, Ren J, et al (2011). A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Nanotechnology, 22, 265105. DOI ScienceOn |
43 | Guo L, Fan L, Ren J, et al (2012). Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine, 7, 1449-60. |
44 | Haag C, Stadel D, Zhou S, et al (2011). Identification of c-FLIP(L) and c-FLIP(S) as critical regulators of death receptor-induced apoptosis in pancreatic cancer cells. Gut, 60, 225-37. DOI ScienceOn |
45 | Hafeez BB, Mustafa A, Fischer JW, et al (2014). -Mangostin: a Dietary antioxidant derived from the pericarp of Garcinia mangostana L. inhibits pancreatic tumor growth in xenograft mouse model. Antioxid Redox Signal, doi:10.1089/ars.2013.5212.. DOI ScienceOn |
46 | Huang M, Tang SN, Upadhyay G, et al (2014). Embelin suppresses growth of human pancreatic cancer xenografts, and pancreatic cancer cells isolated from KrasG12D mice by inhibiting akt and sonic hedgehog pathways. PLoS One, 2, 92161. |
47 | Haselmann V, Kurz A, Bertsch U, et al (2014). Nuclear death receptor TRAIL-R2 inhibits maturation of Let-7 and promotes proliferation of pancreatic and other tumor cells. Gastroenterology, 146, 278-90. DOI ScienceOn |
48 | Hinz S, Trauzold A, Boenicke L, et al (2000). Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAILreceptor-mediated apoptosis. Oncogene, 19, 5477-86. DOI ScienceOn |
49 | Hoshi H, Sawada T, Uchida M, et al (2013). MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways. Int J Oncol, 42, 887-93. |
50 | Ibrahim SM, Ringel J, Schmidt C, et al (2001). Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas, 23, 72-9. DOI ScienceOn |
51 | Kannappan R, Ravindran J, Prasad S, et al (2010). Gammatocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol Cancer Ther, 9, 2196-207. DOI |
52 | Kim H, Zhai G, Samuel SL, et al (2012). Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma. Mol Cancer Ther, 11, 405-15. DOI |
53 | Kim JH, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through upregulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27. DOI ScienceOn |